张春红,刘有平,王鑫,李秋影,邸欣
ZHANG Chun-hong,LIU You-ping,WANG Xin,LI Qiu-ying,DI Xin(School of Pharmacy

• 1:沈阳药科大学药学院

摘要(Abstract)：

目的研究雄性Wistar大鼠灌胃盐酸法舒地尔的吸收和分布特征,为临床试验提供依据。方法大鼠分别灌胃和静注给予4 mg.kg-1盐酸法舒地尔后,采用液相色谱-串联质谱(LC-MS/MS)法测定血浆和组织中法舒地尔和羟基法舒地尔的浓度,用DAS 2.1.1软件计算主要药动学参数。结果灌胃给药后,大鼠血浆中法舒地尔和羟基法舒地尔的ρmax分别为(30.4±17.9)和(199±108)μg.L-1t,max分别为(0.3±0.1)和(0.7±0.7)h,AUC0-t分别为(53.3±13.7)和(434±223)μg.h.L-1t,1/2分别为(2.7±1.6)和(2.3±1.0)h,法舒地尔的绝对生物利用度为10.2%。组织分布试验表明,给药后0.25 h大部分组织中法舒地尔和羟基法舒地尔的浓度即达到峰值,6 h后各组织中的药物浓度均显著下降,法舒地尔主要分布在胃和小肠组织,其次在肝、脾等组织,羟基法舒地尔主要分布在肝组织,其次在胃、肠、肾等组织。结论大鼠灌胃盐酸法舒地尔后,在胃肠道迅速被吸收,并较快分布于全身各组织,血浆和组织中羟基法舒地尔的浓度明显高于法舒地尔的浓度,法舒地尔和羟基法舒地尔均没有组织蓄积现象。
Objective To study absorption and tissue distribution of fasudil and hydroxyfasudil after intragastric administration of fasudil hydrochloride to Wistar rats. Methods Fasudil hydrochloride(4 mg·kg-1)was administrated by an i.g.and i.v.administration to Wistar rats.The concentration of fasudil and its active metabolite of hydroxyfasudil in rat plasma and tissues were detected by LC-MS/MS,the pharmacokinetic parameters were calculated by DAS 2.1.1. Results The ρmax of both analytes were(30.4±17.9)and(199±108)μg·L-1,tmax were(0.3±0.1)and(0.7±0.7)h,AUC0-t were(53.3±13.7)and(434±223)μg·h·L-1,t1/2 were(2.7±1.6)and(2.3±1.0)h,respectively.The absolute bioavailability of fasudil was 10.2%.The concentration of fasudil and hydroxyfasudil in tissues were markedly after 0.25 h following i.g.administration,and they were eliminated out after 6 h.Fasudil was mainly distributed in stomach and intestine,secondly were in liver and spleen.Hydroxyfasudil was mainly distributed in liver,secondly were in stomach,intestine,kidney and so on. Conclusions Fasudil and hydroxyfasudil are immediately absorption and distribution after i.g.administration to rat,especially in the tissues with affluent blood.The concentration of fasudil and hydroxyfasudil are much higher than that of fasudil in plasma and tissues,and no accumulation is found.

关键词(KeyWords)： 法舒地尔;羟基法舒地尔;大鼠;吸收;组织分布
fasudil;hydroxyfasudil;rat;absorption;tissue distribution

Abstract:

Keywords:

基金项目(Foundation): 国家十一五科技重大专项“辽宁省重大新药创制综合平台”(2009ZX09301-012)

作者(Author): 张春红,刘有平,王鑫,李秋影,邸欣
ZHANG Chun-hong,LIU You-ping,WANG Xin,LI Qiu-ying,DI Xin(School of Pharmacy

DOI: 10.14066/j.cnki.cn21-1349/r.2011.11.007

参考文献(References)：

• [1]张明,孙晓川.法舒地尔的药理作用及其临床应用的研究进展[J].山西医科大学学报,2007,38(4):369-373.
• [2]郝春华,王维亭,赵专友,等.法舒地尔对心脑血管疾病的药理作用及临床应用[J].现代药物与临床,2010,25(6):411-416.
• [3]DONG M,YAN B P,LIAO J K,et al.Rho-kinase inhi-bition:a novel therapeutic target for the treatment ofcardio vascular diseases[J].Drug Discovery Today,2010.8,15(15/16):622-629.
• [4]HIROAKI S,KATSUHIKO H,HIROYUKI I,et al.An-ti-anginal effect of fasudil,a Rho-kinase inhibitor,inpatients with stable effort angina:a multicenter study[J].J Cardiovasc Pharmacol2,0024,0:751-761.
• [5]刘艳艳.法舒地尔的药理作用及其临床应用[J].中国城乡企业卫生,2010.10,139:43-45.
• [6]旭化成株式会社.法舒地尔盐酸盐缓释口服制剂:中国1,307476A[P].2000-12-28.
• [7]姚小青.一种盐酸法舒地尔口服制剂:中国,1813762A[P].2006-08-09.
• [8]化学药物非临床药代动力学研究技术指导原则.[H]GPT5-12,005.3.
• [9]CHEN Hua-ying,LIN Yang,HAN Min,et al.Simulta-neous quantitative analysis of fasudil and its active me-tabolite in human plasma by liquid chromatography e-lectro-spray tandem mass spectrometry[J].J Journal ofPharmaceutical and Biomedical Analysis,2010,52:242-248.
• [10]韩敏,陈华英,林阳,等.单次静滴法舒地尔的药动学[J].Chin Pharm J,2011,46(4):292-296.
• [11]刘袁媛,邸欣,孙毓庆.法舒地尔和安非他酮的药物动力学研究[D].中国优秀硕士论文全文数据库.2011:S2.
• [12]钟大放.以加权最小二乘法建立生物分析标准曲线的若干问题[J].药物分析杂志,1996,16(5):343-346.